[Skip to content](https://oculogica.com/oculogicas-eyebox-shines-in-new-study-published-in-military-medicine/#content)

August 20, 2024, New Richmond, WI

Oculogica Inc. is pleased to highlight a publication this week by a Department of

Defense based research team on the company’s EyeBOX concussion diagnostic

technology. The study, Comparative Performance of Three Eye-Tracking Devices in

Detection of Mild Traumatic Brain Injury in Acute Versus Chronic Subject Populations,

was published in Military Medicine on August 17, 2024. The study was led by Dr. John

King of the Center for Military Psychology and Neuroscience, Walter Reed Army

Institute of Research (WRAIR), Silver Spring, MD. The study team also included Ms.

Chantele Friend, of the Henry M. Jackson Foundation for the Advancement of Military

Medicine, Dr. Dong Zhang of Bloomberg University, and Major Walter Carr, also of

WRAIR.

The research included 216 participants ages 18-45 in 3 groups: those with a recent

concussion within 72 hours of injury, those with a concussion sustained several months

or more ago, and a group with no history of concussion. Participants underwent tests

with all three eye-tracking based concussion diagnostics – NeuroSync’s EYE-SYNC,

Oculogica’s EyeBOX and NeuroKinetics’ IPAS devices, in random order to prevent bias

due to fatigue.

The study compared the performance and usability of the three eye-tracking devices

with each other and a clinical reference standard for concussion, also referred to as mild

traumatic brain injury (mTBI). Measures from Oculogica’s EyeBOX demonstrated the

highest diagnostic sensitivity for those with recent concussion and the highest specificity

for those with a concussion sustained a month or more ago. The EyeBOX also had the

lowest rate of poor-quality scans, was rated easiest to use, and cited as the only device

that does not require calibration.

“Using eye-tracking technology is a needed step in the right direction for concussion

diagnosis. Having an objective way to better understand what is going on with a

patient’s brain is critical to getting patients better, more quickly. We’re thrilled with the

outcome of this study, validating the quality of our technology by a completely

independent research group,” said Oculogica CEO Rosina Samadani, Ph.D.

The EyeBOX technology is the first non-invasive concussion diagnostic approved by the

FDA for aid in the diagnosis of concussion that does not require a pre-injury baseline

test. Leading clinics, such as the Mayo Clinic, Midwest Orthopedics at Rush University

and Minneapolis Clinic of Neurology, amongst others, offer the technology.

The full publication by Dr. King and his colleagues, and other publications on

Oculogica’s EyeBOX technology, are available here: [https://oculogica.com/publications/.](https://oculogica.com/publications/)

Scroll to Top